UBS Group AG Takes $2.59 Million Position in Billiontoone, Inc. $BLLN

UBS Group AG bought a new stake in Billiontoone, Inc. (NASDAQ:BLLN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 31,599 shares of the company’s stock, valued at approximately $2,586,000. UBS Group AG owned about 0.07% of Billiontoone as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Billiontoone in the fourth quarter valued at approximately $1,348,000. Baillie Gifford & Co. purchased a new stake in Billiontoone in the fourth quarter valued at approximately $103,786,000. Massachusetts Financial Services Co. MA purchased a new stake in Billiontoone in the fourth quarter valued at approximately $13,373,000. FNY Investment Advisers LLC purchased a new stake in Billiontoone in the fourth quarter valued at approximately $497,000. Finally, Green Alpha Advisors LLC purchased a new stake in Billiontoone in the fourth quarter valued at approximately $436,000.

Billiontoone Price Performance

Shares of BLLN stock opened at $84.52 on Wednesday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The firm has a market cap of $3.89 billion and a P/E ratio of 153.67. The stock’s 50 day simple moving average is $81.95. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. The company’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.39) earnings per share. Analysts anticipate that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on BLLN. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, May 15th. Guggenheim upped their price objective on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. upped their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, BTIG Research reduced their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.